Literature DB >> 25841498

Mining the ACCENT database: a review and update.

Lindsay A Renfro1, Qian Shi2, Daniel J Sargent2.   

Abstract

The database of the Adjuvant Colon Cancer End Points (ACCENT) Group was assembled to address questions in early stage colon cancer that could be best answered by information pooled across many similar trials. Today, the ACCENT database contains individual patient-level data from over 33,000 patients enrolled onto 25 adjuvant colon cancer trials conducted between 1977 and 2008. Since its flagship analysis of 3-year disease-free survival as a surrogate endpoint for 5-year overall survival in 2005, the ACCENT group has produced many noteworthy scientific findings addressing a variety of clinical questions, which we describe here. Additionally, we provide an overview of the history, collaboration, construction, principles, and future of the ACCENT database, as it has set a precedent for multi-trial database creation in other types of cancer.

Entities:  

Keywords:  Adjuvant Colon Cancer End Points (ACCENT) Group; colon cancer; database

Year:  2013        PMID: 25841498      PMCID: PMC4407359          DOI: 10.3978/j.issn.2304-3865.2013.03.05

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  18 in total

1.  A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

Authors:  D J Sargent; R M Goldberg; S D Jacobson; J S Macdonald; R Labianca; D G Haller; L E Shepherd; J F Seitz; G Francini
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

2.  Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.

Authors:  Joleen Hubbard; David M Thomas; Greg Yothers; Erin Green; Charles Blanke; Michael J O'Connell; Roberto Labianca; Qian Shi; Archie Bleyer; Aimery de Gramont; Daniel Sargent
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.

Authors: 
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

5.  Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Authors:  Greg Yothers; Daniel J Sargent; Norman Wolmark; Richard M Goldberg; Michael J O'Connell; Jacqueline K Benedetti; Leonard B Saltz; James J Dignam; A William Blackstock
Journal:  J Natl Cancer Inst       Date:  2011-10-12       Impact factor: 13.506

6.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

7.  Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.

Authors:  Frank A Sinicrope; Nathan R Foster; Greg Yothers; Al Benson; Jean Francois Seitz; Roberto Labianca; Richard M Goldberg; Aimery Degramont; Michael J O'Connell; Daniel J Sargent
Journal:  Cancer       Date:  2013-01-10       Impact factor: 6.860

8.  Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

Authors:  Michael J O'Connell; Megan E Campbell; Richard M Goldberg; Axel Grothey; Jean-François Seitz; Jacqueline K Benedetti; Thierry André; Daniel G Haller; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

9.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

10.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; P J Goodman; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

View more
  5 in total

1.  ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Authors:  Lindsay A Renfro; Axel Grothey; Yuan Xue; Leonard B Saltz; Thierry André; Chris Twelves; Roberto Labianca; Carmen J Allegra; Steven R Alberts; Charles L Loprinzi; Greg Yothers; Daniel J Sargent
Journal:  J Natl Cancer Inst       Date:  2014-10-29       Impact factor: 13.506

Review 2.  Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Authors:  Richard M Goldberg; Richard Adams; Marc Buyse; Cathy Eng; Axel Grothey; Thierry André; Alberto F Sobrero; Stuart M Lichtman; Al B Benson; Cornelis J A Punt; Tim Maughan; Tomasz Burzykowski; Dirkje Sommeijer; Everardo D Saad; Qian Shi; Elisabeth Coart; Benoist Chibaudel; Miriam Koopman; Hans-Joachim Schmoll; Takayuki Yoshino; Julien Taieb; Niall C Tebbutt; John Zalcberg; Josep Tabernero; Eric Van Cutsem; Alastair Matheson; Aimery de Gramont
Journal:  J Natl Cancer Inst       Date:  2022-06-13       Impact factor: 11.816

3.  Leveraging the power of pooled data for cancer outcomes research.

Authors:  Kiara Hugh-Yeun; Winson Y Cheung
Journal:  Chin J Cancer       Date:  2016-08-02

4.  The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.

Authors:  Richard M Goldberg; Lai Wei; Soledad Fernandez
Journal:  Oncologist       Date:  2017-06-15

Review 5.  Sharing individual participant data: through a systematic reviewer lens.

Authors:  Larysa H M Rydzewska; Lesley A Stewart; Jayne F Tierney
Journal:  Trials       Date:  2022-02-21       Impact factor: 2.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.